Spots Global Cancer Trial Database for cell therapy
Every month we try and update this database with for cell therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | NCT06197672 | Acute Myeloid L... | CD4CAR | 18 Years - | Indiana University | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells | NCT00562666 | Hepatocellular ... | T gamma delta l... | 18 Years - | Rennes University Hospital | |
| QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | NCT03027128 | Solid Tumor | haNK™ for Infus... | 18 Years - | ImmunityBio, Inc. | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) | NCT04752358 | Esophageal Canc... Esophagogastric... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma | NCT03250325 | Synovial Sarcom... | TBI-1301 Cyclophosphamid... | 18 Years - | Takara Bio Inc. | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | NCT02592577 | Non-Small Cell ... Carcinoma | Autologous Gene... | 18 Years - | Adaptimmune | |
| Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | NCT03592706 | HepatoCellular ... Liver Cancer | IKC (Immune Kil... TACE (Transcath... | 20 Years - 79 Years | Ivy Life Sciences, Co., Ltd | |
| RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | NCT04762225 | Head and Neck S... Melanoma Cervical Cancer | RPTR-168 | 18 Years - | Repertoire Immune Medicines | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | NCT02360579 | Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | NCT03190941 | Pancreatic Canc... Gastric Cancer Gastrointestina... Colon Cancer Rectal Cancer | Cyclophosphamid... Fludarabine Anti-KRAS G12V ... Aldesleukin | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | NCT04044859 | Endometrial Can... Esophageal Canc... Esophagogastric... Gastric (Stomac... Head and Neck C... Melanoma Ovarian Cancer Non-small Cell ... Urothelial Canc... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | NCT00151645 | Metastatic Rena... | activated lymph... | 18 Years - 70 Years | Rennes University Hospital | |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | NCT06302062 | Advanced Solid ... Tumor Associate... Immunotherapy | Tumor Associate... cyclophosphamid... IL-2 Serplulimab Inj... | 18 Years - 75 Years | Guangzhou FineImmune Biotechnology Co., LTD. | |
| ITIL-168 in Advanced Melanoma | NCT05050006 | Advanced Cutane... | ITIL-168 | 18 Years - | Instil Bio | |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | NCT04911478 | Lymphoma, Folli... Lymphoma, Mantl... Marginal Zone L... Primary Mediast... Diffuse Large B... Lymphoma, Non-H... | ADI-001 | 18 Years - | Adicet Bio, Inc | |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer | NCT03419559 | Non Small Cell ... | LN-145 Durvalumab | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Investigator Initiated Phase 1 Study of TBI-1301 | NCT02366546 | Solid Tumors | TBI-1301 Cyclophosphamid... Fludarabine | 20 Years - | Mie University | |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | NCT03083873 | Squamous Cell C... | LN-145 LN-145-S1 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | NCT03300843 | Melanoma Gastrointestina... Breast Cancer Ovarian Cancer Pancreatic Canc... | Peptide loaded ... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| PBMC-based Leukocyte Immunotherapy | NCT06172894 | Advanced Solid ... | APN401 | 18 Years - | invIOs GmbH | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors | NCT05831033 | Solid Tumor | BEN101 | 18 Years - 70 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | NCT03745326 | Gastrointestina... Pancreatic Canc... Gastric Cancer Colon Cancer Rectal Cancer | Cyclophosphamid... Fludarabine Aldesleukin anti-KRAS G12D ... | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors | NCT06013111 | Carcinoma | Intravenous inf... | 18 Years - 70 Years | China Medical University, China | |
| ITIL-306 in Advanced Solid Tumors | NCT05397093 | Epithelial Ovar... Non-small Cell ... Renal Cell Carc... | ITIL-306 | 18 Years - | Instil Bio | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| ITIL-168 in Advanced Solid Tumors | NCT05393635 | Cervical Cancer Head and Neck S... Non-small Cell ... | ITIL-168 | 18 Years - | Instil Bio | |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | NCT02203825 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CM-CS1 T-cell i... | 18 Years - | Celyad Oncology SA | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | NCT06302062 | Advanced Solid ... Tumor Associate... Immunotherapy | Tumor Associate... cyclophosphamid... IL-2 Serplulimab Inj... | 18 Years - 75 Years | Guangzhou FineImmune Biotechnology Co., LTD. | |
| LTFU for All Cell and Gene Therapy Studies | NCT06194461 | Hepatocellular ... Prostate Cancer | AZD5851 AZD0754 | 18 Years - 130 Years | AstraZeneca | |
| ITIL-168 in Advanced Melanoma | NCT05050006 | Advanced Cutane... | ITIL-168 | 18 Years - | Instil Bio | |
| SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer | NCT04408898 | Head and Neck C... | ADP-A2M4 in com... | 18 Years - 75 Years | Adaptimmune | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | NCT06056752 | B-cell Acute Ly... | QH103 Cell Inje... Fludarabine Cyclophosphamid... | 14 Years - | Anhui Provincial Hospital | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | NCT05207722 | Metastatic HER2... | CYNK-101 Pembrolizumab Trastuzumab Recombinant Hum... Cyclophosphamid... Fludarabine Mesna | 18 Years - 75 Years | Celularity Incorporated | |
| Study of INKmune in Patients With mCRPC (CaRe Prostate) | NCT06056791 | Cancer Metastatic Cast... mCRPC | INKmune | 18 Years - | Inmune Bio, Inc. | |
| Investigator Initiated Phase 1 Study of TBI-1301 | NCT02366546 | Solid Tumors | TBI-1301 Cyclophosphamid... Fludarabine | 20 Years - | Mie University | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | NCT02203825 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CM-CS1 T-cell i... | 18 Years - | Celyad Oncology SA | |
| A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors | NCT06101082 | Solid Tumor | Intravenous inf... | 18 Years - 70 Years | China Medical University, China | |
| Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H) | NCT01389661 | Maxillary Cyst Bone Loss of Su... | MSV treatment | 18 Years - 65 Years | Red de Terapia Celular | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors | NCT03391791 | Solid and Hemat... | Genetically eng... | 18 Years - | Adaptimmune | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy | NCT01329354 | Follicular Lymp... Follicular Non-... Autologous Effe... | Autologous effe... | 18 Years - 75 Years | Clinica Universidad de Navarra, Universidad de Navarra | |
| Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients | NCT04634435 | Multiple Myelom... | CIML NK Cells p... | 18 Years - 75 Years | Biohaven Pharmaceuticals, Inc. | |
| a Single-arm, Single-center, Open Clinical Study | NCT06431100 | Gastric Cancer Esophageal Canc... Cervical Cancer Non-Small Cell ... Triple Negative... | TCR T-cells | 18 Years - 75 Years | Beijing Geekgene Technology Co., LTD | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | NCT04489420 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Cyclophosphamid... Immunosuppressi... Immunologic Fac... Physiological E... Molecular Mecha... Antiviral Agent... Anti-infective ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... | CYNK001-IV CYNK001-IT | 18 Years - | Celularity Incorporated | |
| "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | NCT04317248 | Hepatocellular ... | Cyclophosphamid... Multiple Signal... | 18 Years - 70 Years | Third Affiliated Hospital, Sun Yat-Sen University | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis | NCT05451212 | MuSK Myasthenia... | MuSK-CAART | 18 Years - | Cabaletta Bio | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab | NCT04536922 | Metastatic HPV-... | Cyclophosphamid... Fludarabine Aldesleukin Pembrolizumab (... Individual Pati... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers | NCT05302037 | Cancer Malignancy Refractory Canc... Relapsed Cancer | Allogeneic NKG2... | 21 Years - | CytoMed Therapeutics Pte Ltd | |
| MVX-ONCO-1 in Patients With Solid Tumor | NCT02193503 | Solid Tumor Cancer | Treatment | 18 Years - | Maxivax SA |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
